Hypothesis · not a trading signal
Q3 FY2026 · Published 2026-06-24 · Source checked 2026-09-06
- 01 / What the issuer reported
- Revenue was $41.46bn versus $9.30bn a year earlier; the company reported $18.3bn adjusted free cash flow.
- 02 / Our hypothesis — not established alpha
- HBM mix and supply discipline could improve through-cycle returns; extrapolating a memory boom is the central valuation trap.
- 03 / What to measure next
- HBM contract economics, bit supply, pricing, inventory, capex and cash margins across cycles.
- 04 / What would challenge the thesis
- Reassess if supply expands faster than demand while pricing and inventory turn adverse; test a downcycle explicitly.
- 05 / Appropriate valuation method
- Through-cycle DCF and normalized earnings, not a low P/E computed from peak EPS.
- 06 / Still missing
- Missing: filing reconciliation of exceptional results, supply assumptions and contract protections.
No measured consensus gap or approved price target. A familiar good business can still be an expensive stock.